(Reuters) - Advisers to the U.S. Food and Drug Administration on Tuesday recommended the authorization of Moderna (NASDAQ:MRNA) Inc's COVID-19 vaccine for children and teens aged 6 to 17 years of age.
(Reuters) - Advisers to the U.S. Food and Drug Administration on Tuesday recommended the authorization of Moderna (NASDAQ:MRNA) Inc's COVID-19 vaccine for children and teens aged 6 to 17 years of age.